Blood test may predict which rectal cancer patients can skip surgery
NCT ID NCT05081024
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether a simple blood test can help doctors decide if rectal cancer patients can avoid surgery and keep their rectum. Researchers will measure tiny bits of tumor DNA in the blood (ctDNA) before, during, and after standard treatment. The goal is to see if changes in ctDNA levels match how well the tumor responds, potentially leading to more personalized, organ-saving care. About 50 adults with stage II or III rectal cancer will participate.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutch
RECRUITINGSeattle, Washington, 98109, United States
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can diet and vitamin c supercharge rectal cancer treatment?
- AI as a surgical Co-Pilot: predicting difficulty in rectal cancer
- A new radiation combo may spare the rectum in early cancer
- Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
- Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
- Can a beetroot drink spot dangerous surgical leaks before they turn deadly?